# Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

> **NCT01531205** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 2 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Androgen Ablation
- **DRUG:** Cabazitaxel
- **DRUG:** Salvage Therapy
- **DRUG:** Neoadjuvant Treatment - Hormonal Therapy
- **DRUG:** Neoadjuvant Treatment - Cabazitaxel

## Key facts

- **NCT ID:** NCT01531205
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2013-09
- **Final completion:** 2013-10
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2014-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01531205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01531205, "Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01531205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*